The University of Colorado Anshutz Medical Campus MD/PhD Program was established in 1983 and obtained NIH/MSTP funding in 1993. This is the 4th competitive review, with an unchanged slot number (14-15) for the past 15 years, despite IRG recommendations for increased slots. The goal of this Program is to train dual-degree students to become outstanding physician-scientists and future leaders in biomedical research. To accomplish this goal, we select students from an ever-increasing national applicant pool, seeking out those candidates whose record of research, academic, and leadership achievements are exemplary. Our pool size has increased significantly, from 55 in 1997, to 154 in 2007, and 328 in 2011. We now matriculate ~10 students annually, with a current total of 70 students (46% female; 14% URM; 5% disability; 14% disadvantaged). The selected MSTP students enter a revised, flexible, yet highly rigorous training program that inter-digitates graduate and medical courses in the first two years, followed by 3-4 years of thesis work, and is completed with 20-25 months of clinical work. A MSTP-specific Molecules to Medicine course, Seminar Series, and a 6-year Longitudinal Clinical experience have been specifically developed for our students. For thesis research, students choose from 16 graduate training programs located at three sites: the new Anschutz Medical Campus (AMC), National Jewish Health (NJH), and the University of Colorado at Boulder (CU-Boulder). These three training sites have a combined grant income totaling nearly $1B. Biochemistry, Chemical & Biological Engineering, and Molecular, Cellular and Developmental Biology Programs are available at CU-Boulder; whereas Bioengineering, Cancer Biology, Cell Biology, Stem Cells & Development, Computational Bioscience, Human Medical Genetics, Immunology, Microbiology, Molecular Biology, Neurosciences, Pharmacology, Physiology & Biophysics, Reproductive Science, and Structural Biology & Biophysics Programs are available at the AMC/NJH integrated sites. To enhance the success of our MSTP students, we provide career guidance beyond the PhD thesis years, and we work diligently to place our graduates in elite residencies and fellowships. Since 1983, 163 students have matriculated, 11 have left the program, 82 graduated with both degrees in 8.2 years and 51 completed all of their training with the majority pursuing research in academics, the CDC, or industry. The new Campus provides state-of-the-art education, research and clinical facilities, thus we have continued to increase faculty and training opportunities.

Public Health Relevance

Clinical disorders, such as Alzheimer's, auto-immunity, diabetes, cancer, hypertension, obesity and genetic diseases result in significant human suffering, and unnecessary morbidity and mortality. To mitigate the negative impact of these diseases, it is critical to train a cadre of physician-scientists who can identify the most important questions in medicine, and then apply the most rigorous scientific investigation tools to discover disease mechanism, novel treatments, and optimal prevention strategies. Trainees supported by this grant will become the future biomedical physician-scientists who will work towards increasing our understanding of fundamental pathogenesis of disease and cutting-edge approaches to treat patients.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM008497-25
Application #
9308975
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Gindhart, Joseph G
Project Start
1993-07-01
Project End
2018-06-30
Budget Start
2017-07-01
Budget End
2018-06-30
Support Year
25
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Garcia, Tamara B; Fosmire, Susan P; Porter, Christopher C (2018) Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine. Leuk Res 64:30-33
Pei, Shanshan; Minhajuddin, Mohammad; Adane, Biniam et al. (2018) AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. Cell Stem Cell 23:86-100.e6
Estin, Miriam L; Thompson, Scott B; Traxinger, Brianna et al. (2017) Ena/VASP proteins regulate activated T-cell trafficking by promoting diapedesis during transendothelial migration. Proc Natl Acad Sci U S A 114:E2901-E2910
Yang, Yimu; Haeger, Sarah M; Suflita, Matthew A et al. (2017) Fibroblast Growth Factor Signaling Mediates Pulmonary Endothelial Glycocalyx Reconstitution. Am J Respir Cell Mol Biol 56:727-737
Keysar, Stephen B; Le, Phuong N; Miller, Bettina et al. (2017) Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. J Natl Cancer Inst 109:
White, Jason T; Cross, Eric W; Kedl, Ross M (2017) Antigen-inexperienced memory CD8+ T cells: where they come from and why we need them. Nat Rev Immunol 17:391-400
Scarborough, Hannah A; Helfrich, Barbara A; Casás-Selves, Matias et al. (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res 23:1531-1541
St Clair, J Benjamin; Detanico, Thiago; Aviszus, Katja et al. (2017) Immunogenicity of Isogenic IgG in Aggregates and Immune Complexes. PLoS One 12:e0170556
Bishop, Nicholas H; Nelsen, Michelle K; Beard, K Scott et al. (2017) Differential Impact of Chronic Hyperglycemia on Humoral Versus Cellular Primary Alloimmunity. Diabetes 66:981-986
Garcia, Tamara B; Snedeker, Jonathan C; Baturin, Dmitry et al. (2017) A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. Mol Cancer Ther 16:2058-2068

Showing the most recent 10 out of 159 publications